Condition: Diffuse Large B Cell Lymphoma · Sponsor: University of Utah
The purpose of this clinical trial is to assess the safety and tolerability of ration therapy followed by receiving epcoritamab or glofitamab in patients with relapsed/refractory diffuse large B-cell lymphoma.
This description comes directly from the study's public registry record.
David Samuel · 801-587-4713 · david.samuel@hci.utah.edu
Allison Bock, MD · 801-585-0255 · Allison.Bock@hci.utah.edu
Always discuss trial participation with your own doctor first.
| Huntsman Cancer Institute at University of Utah | Salt Lake City, Utah, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07528352